B D Anawalt1, M Y Roth1, J Ceponis2,3, V Surampudi3, J K Amory1, R S Swerdloff3, P Y Liu3, C Dart4, W J Bremner1, R Sitruk-Ware5, N Kumar5, D L Blithe6, S T Page1, C Wang3. 1. Department of Medicine, University of Washington, Seattle, WA, USA. 2. Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 3. Department of Medicine, Division of Endocrinology, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA. 4. Health Decisions, Durham, NC, USA. 5. Center for Biomedical Research, Population Council, New York, NY, USA. 6. Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: Novel male-based contraceptives are needed to broaden family planning choices. A progestin, Nestorone® (Nes) gel, plus a testosterone (T) gel suppresses sperm concentrations to levels associated with effective contraception in normal men. However, administration of two gels on different parts of the body daily is impractical. OBJECTIVE: Compare the effectiveness of daily application of a single, combined 8.3 mg Nes-62.5 mg T gel (Nes-T) vs. 62.7 mg T gel to suppress serum FSH and LH concentrations to ≤1.0 IU/L (a threshold associated with suppression of sperm concentrations to ≤1 million and effective contraception) and to compare the pharmacokinetics of serum Nes and T concentrations between the gel groups. DESIGN: We conducted a 28-day, double-blind, controlled trial of 44 healthy men randomized todaily Nes-T or T gel with measurement of hormones at baseline, treatment, and recovery and during 24-h pharmacokinetic studies on days 1 and 28 of treatment. RESULTS: Of the subjects who met pre-defined inclusion criteria, 84% of the Nes-T group suppressed serum gonadotropin concentrations to ≤1.0 IU/L at days 21-28 vs. 16.7% in the T group (p < 0.001). On day 1, Nes concentrations rose significantly above baseline by 2 h and continued to rise up to 24 h after Nes-T gel application. Nes concentrations were not detectable in the T group. Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01). There were no serious adverse events in either group. About 80% of the subjects reported satisfaction with both gels. CONCLUSION: Daily Nes-T gel effectively and safely suppresses serum gonadotropins and is acceptable to most men. It should be studied further in efficacy trials of hormonal male contraception.
RCT Entities:
BACKGROUND: Novel male-based contraceptives are needed to broaden family planning choices. A progestin, Nestorone® (Nes) gel, plus a testosterone (T) gel suppresses sperm concentrations to levels associated with effective contraception in normal men. However, administration of two gels on different parts of the body daily is impractical. OBJECTIVE: Compare the effectiveness of daily application of a single, combined 8.3 mg Nes-62.5 mg T gel (Nes-T) vs. 62.7 mg T gel to suppress serum FSH and LH concentrations to ≤1.0 IU/L (a threshold associated with suppression of sperm concentrations to ≤1 million and effective contraception) and to compare the pharmacokinetics of serum Nes and T concentrations between the gel groups. DESIGN: We conducted a 28-day, double-blind, controlled trial of 44 healthy men randomized to daily Nes-T or T gel with measurement of hormones at baseline, treatment, and recovery and during 24-h pharmacokinetic studies on days 1 and 28 of treatment. RESULTS: Of the subjects who met pre-defined inclusion criteria, 84% of the Nes-T group suppressed serum gonadotropin concentrations to ≤1.0 IU/L at days 21-28 vs. 16.7% in the T group (p < 0.001). On day 1, Nes concentrations rose significantly above baseline by 2 h and continued to rise up to 24 h after Nes-T gel application. Nes concentrations were not detectable in the T group. Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01). There were no serious adverse events in either group. About 80% of the subjects reported satisfaction with both gels. CONCLUSION: Daily Nes-T gel effectively and safely suppresses serum gonadotropins and is acceptable to most men. It should be studied further in efficacy trials of hormonal male contraception.
Authors: C W Martin; R A Anderson; L Cheng; P C Ho; Z van der Spuy; K B Smith; A F Glasier; D Everington; D T Baird Journal: Hum Reprod Date: 2000-03 Impact factor: 6.918
Authors: A F Glasier; R Anakwe; D Everington; C W Martin; Z van der Spuy; L Cheng; P C Ho; R A Anderson Journal: Hum Reprod Date: 2000-03 Impact factor: 6.918
Authors: C Wang; N Berman; J A Longstreth; B Chuapoco; L Hull; B Steiner; S Faulkner; R E Dudley; R S Swerdloff Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Leo Turner; Ann J Conway; Mark Jimenez; Peter Y Liu; Elise Forbes; Robert I McLachlan; David J Handelsman Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: Subarna Sinha; Merrill Knapp; John Pywtorak; Greg McCain; Kenneth Wingerden; Colin VanDervoort; J Mark Gondek; Peter Madrid; Toufan Parman; Stephen Gerrard; Jill E Long; Diana L Blithe; Stuart Moss; Min S Lee Journal: Biol Reprod Date: 2021-12-20 Impact factor: 4.161
Authors: Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang Journal: Best Pract Res Clin Obstet Gynaecol Date: 2020-02-19 Impact factor: 5.237